{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,12]],"date-time":"2026-11-12T13:43:48Z","timestamp":1794491028139,"version":"4.9.1"},"reference-count":57,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,2,14]],"date-time":"2024-02-14T00:00:00Z","timestamp":1707868800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,2,14]],"date-time":"2024-02-14T00:00:00Z","timestamp":1707868800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Med"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Establishing whether there is a potential relationship between glucagon-like peptide 1 receptor agonists (GLP-1RAs) and suicidal or self-injurious behaviors (SSIBs) is crucial for public safety. This study investigated the potential association between GLP-1RAs and SSIBs by exploring the FDA Adverse Event Reporting System (FAERS) database.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A disproportionality analysis was conducted using post-marketing data from the FAERS repository (2018 Q1 to 2022 Q4). SSIB cases associated with GLP-1RAs were identified and analyzed through disproportionality analysis using the information component. The parametric distribution with a goodness-of-fit test was employed to analyze the time-to-onset, and the \u03a9 shrinkage was used to evaluate the potential effect of co-medication on the occurrence of SSIBs.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>In total, 204 cases of SSIBs associated with GLP-1RAs, including semaglutide, liraglutide, dulaglutide, exenatide, and albiglutide, were identified in the FAERS database. Time-of-onset analysis revealed no consistent mechanism for the latency of SSIBs in patients receiving GLP-1RAs. The disproportionality analysis did not indicate an association between GLP-1RAs and SSIBs. Co-medication analysis revealed 81 cases with antidepressants, antipsychotics, and benzodiazepines, which may be proxies of mental health comorbidities.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>We found no signal of disproportionate reporting of an association between GLP-1RA use and SSIBs. Clinicians need to maintain heightened vigilance on patients premedicated with neuropsychotropic drugs. This contributes to the greater acceptance of GLP-1RAs in patients with type 2 diabetes mellitus or obesity.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Graphical Abstract<\/jats:title>\n                  <\/jats:sec>","DOI":"10.1186\/s12916-024-03274-6","type":"journal-article","created":{"date-parts":[[2024,2,14]],"date-time":"2024-02-14T00:02:26Z","timestamp":1707868946000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":84,"title":["Exploration of the potential association between GLP-1 receptor agonists and suicidal or self-injurious behaviors: a pharmacovigilance study based on the FDA Adverse Event Reporting System database"],"prefix":"10.1186","volume":"22","author":[{"given":"Jianxing","family":"Zhou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"You","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Baohua","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Songjun","family":"Long","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li-e","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yunhui","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chengliang","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yifan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maobai","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1640-7385","authenticated-orcid":false,"given":"Xuemei","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,2,14]]},"reference":[{"key":"3274_CR1","doi-asserted-by":"publisher","first-page":"2200","DOI":"10.1161\/CIRCULATIONAHA.117.032759","volume":"137","author":"I Lingvay","year":"2018","unstructured":"Lingvay I, Leiter LA. Use of GLP-1 RAs in cardiovascular disease prevention: a practical guide. Circulation. 2018;137:2200\u20132.","journal-title":"Circulation."},{"key":"3274_CR2","doi-asserted-by":"publisher","first-page":"1528","DOI":"10.7326\/M21-0893","volume":"174","author":"E Patorno","year":"2021","unstructured":"Patorno E, Htoo PT, Glynn RJ, Schneeweiss S, Wexler DJ, Pawar A, et al. Sodium-glucose cotransporter-2 inhibitors versus glucagon-like peptide-1 receptor agonists and the risk for cardiovascular outcomes in routine care patients with diabetes across categories of cardiovascular disease. Ann Intern Med. 2021;174:1528\u201341.","journal-title":"Ann Intern Med."},{"key":"3274_CR3","doi-asserted-by":"publisher","first-page":"2050","DOI":"10.7150\/ijbs.59965","volume":"17","author":"X Ma","year":"2021","unstructured":"Ma X, Liu Z, Ilyas I, Little PJ, Kamato D, Sahebka A, et al. GLP-1 receptor agonists (GLP-1RAs): cardiovascular actions and therapeutic potential. Int J Biol Sci. 2021;17:2050\u201368.","journal-title":"Int J Biol Sci"},{"key":"3274_CR4","doi-asserted-by":"publisher","first-page":"944","DOI":"10.1111\/apt.16794","volume":"55","author":"AS Barritt","year":"2022","unstructured":"Barritt AS, Marshman E, Noureddin M. Review article: role of glucagon-like peptide-1 receptor agonists in non-alcoholic steatohepatitis, obesity and diabetes-what hepatologists need to know. Aliment Pharmacol Ther. 2022;55:944\u201359.","journal-title":"Aliment Pharmacol Ther"},{"issue":"11","key":"3274_CR5","doi-asserted-by":"publisher","first-page":"2753","DOI":"10.2337\/dci22-0034","volume":"45","author":"MJ Davies","year":"2022","unstructured":"Davies MJ, Aroda VR, Collins BS, Gabbay RA, Green J, Maruthur NM, et al. Management of Hyperglycemia in Type 2 Diabetes, A consensus report by the american diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care. 2022;45(11):2753\u201386.","journal-title":"Diabetes Care"},{"key":"3274_CR6","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1146\/annurev-med-043021-014919","volume":"74","author":"AM Jastreboff","year":"2023","unstructured":"Jastreboff AM, Kushner RF. New frontiers in obesity treatment: GLP-1 and nascent nutrient-stimulated hormone-based therapeutics. Annu Rev Med. 2023;74:125\u201339.","journal-title":"Annu Rev Med"},{"key":"3274_CR7","doi-asserted-by":"publisher","first-page":"170939","DOI":"10.1016\/j.peptides.2023.170939","volume":"161","author":"CJ Bailey","year":"2023","unstructured":"Bailey CJ, Flatt PR, Conlon JM. An update on peptide-based therapies for type 2 diabetes and obesity. Peptides. 2023;161:170939.","journal-title":"Peptides."},{"key":"3274_CR8","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1016\/S0140-6736(18)31773-2","volume":"392","author":"PM O\u2019Neil","year":"2018","unstructured":"O\u2019Neil PM, Birkenfeld AL, McGowan B, Mosenzon O, Pedersen SD, Wharton S, et al. Efficacy and safety of semaglutide compared with liraglutide and placebo for weight loss in patients with obesity: a randomised, double-blind, placebo and active controlled, dose-ranging, phase 2 trial. Lancet. 2018;392:637\u201349.","journal-title":"Lancet."},{"key":"3274_CR9","doi-asserted-by":"publisher","first-page":"e13177","DOI":"10.1111\/obr.13177","volume":"22","author":"KR Chadda","year":"2021","unstructured":"Chadda KR, Cheng TS, Ong KK. GLP-1 agonists for obesity and type 2 diabetes in children: systematic review and meta-analysis. Obes Rev. 2021;22:e13177.","journal-title":"Obes Rev."},{"key":"3274_CR10","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1038\/s41366-023-01321-5","volume":"47","author":"B Tan","year":"2023","unstructured":"Tan B, Pan X-H, Chew HSJ, Goh RSJ, Lin C, Anand VV, et al. Efficacy and safety of tirzepatide for treatment of overweight or obesity. A systematic review and meta-analysis. Int J Obes (Lond). 2023;47:677\u201385.","journal-title":"Int J Obes (Lond)"},{"key":"3274_CR11","unstructured":"Pfizer Provides Update on GLP-1-RA Clinical Development Program for Adults with Obesity and Type 2 Diabetes Mellitus | Pfizer. https:\/\/www.pfizer.com\/news\/press-release\/press-release-detail\/pfizer-provides-update-glp-1-ra-clinical-development. Accessed 8 Aug 2023."},{"key":"3274_CR12","doi-asserted-by":"publisher","first-page":"384","DOI":"10.2337\/dc22-1148","volume":"46","author":"J Bezin","year":"2023","unstructured":"Bezin J, Gouverneur A, P\u00e9nichon M, Mathieu C, Garrel R, Hillaire-Buys D, et al. GLP-1 receptor agonists and the risk of thyroid cancer. Diabetes Care. 2023;46:384\u201390.","journal-title":"Diabetes Care"},{"key":"3274_CR13","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1001\/jamainternmed.2022.0338","volume":"182","author":"L He","year":"2022","unstructured":"He L, Wang J, Ping F, Yang N, Huang J, Li Y, et al. Association of glucagon-like peptide-1 receptor agonist use with risk of gallbladder and biliary diseases: a systematic review and meta-analysis of randomized clinical trials. JAMA Intern Med. 2022;182:513\u20139.","journal-title":"JAMA Intern Med"},{"key":"3274_CR14","unstructured":"EMA. EMA statement on ongoing review of GLP-1 receptor agonists. European Medicines Agency. 2023. https:\/\/www.ema.europa.eu\/en\/news\/ema-statement-ongoing-review-glp-1-receptor-agonists. Accessed 20 Jul 2023."},{"key":"3274_CR15","doi-asserted-by":"publisher","first-page":"e2020049750","DOI":"10.1542\/peds.2020-049750","volume":"149","author":"KL Fine","year":"2022","unstructured":"Fine KL, Rickert ME, O\u2019Reilly LM, Sujan AC, Boersma K, Chang Z, et al. Initiation of opioid prescription and risk of suicidal behavior among youth and young adults. Pediatrics. 2022;149:e2020049750.","journal-title":"Pediatrics"},{"key":"3274_CR16","first-page":"69","volume":"50","author":"T Takeuchi","year":"2017","unstructured":"Takeuchi T, Takenoshita S, Taka F, Nakao M, Nomura K. The relationship between psychotropic drug use and suicidal behavior in Japan: Japanese adverse drug event report. Pharmacopsychiatry. 2017;50:69\u201373.","journal-title":"Pharmacopsychiatry"},{"key":"3274_CR17","doi-asserted-by":"publisher","first-page":"108390","DOI":"10.1016\/j.pharmthera.2023.108390","volume":"244","author":"X Gonda","year":"2023","unstructured":"Gonda X, Dome P, Serafini G, Pompili M. How to save a life: From neurobiological underpinnings to psychopharmacotherapies in the prevention of suicide. Pharmacol Ther. 2023;244:108390.","journal-title":"Pharmacol Ther"},{"key":"3274_CR18","doi-asserted-by":"publisher","first-page":"e070630","DOI":"10.1136\/bmj-2022-070630","volume":"381","author":"JL Hughes","year":"2023","unstructured":"Hughes JL, Horowitz LM, Ackerman JP, Adrian MC, Campo JV, Bridge JA. Suicide in young people: screening, risk assessment, and intervention. BMJ. 2023;381:e070630.","journal-title":"BMJ"},{"key":"3274_CR19","doi-asserted-by":"publisher","first-page":"4946","DOI":"10.1038\/s41467-020-18742-9","volume":"11","author":"Y Jing","year":"2020","unstructured":"Jing Y, Liu J, Ye Y, Pan L, Deng H, Wang Y, et al. Multi-omics prediction of immune-related adverse events during checkpoint immunotherapy. Nat Commun. 2020;11:4946.","journal-title":"Nat Commun"},{"key":"3274_CR20","doi-asserted-by":"publisher","first-page":"4610","DOI":"10.3390\/cancers14194610","volume":"14","author":"E Raschi","year":"2022","unstructured":"Raschi E, Fusaroli M, Giunchi V, Repaci A, Pelusi C, Mollica V, et al. adrenal insufficiency with anticancer tyrosine kinase inhibitors targeting vascular endothelial growth factor receptor: analysis of the FDA adverse event reporting system. Cancers (Basel). 2022;14:4610.","journal-title":"Cancers (Basel)"},{"key":"3274_CR21","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1002\/cpt.2920","volume":"114","author":"S Xia","year":"2023","unstructured":"Xia S, Gong H, Zhao Y, Guo L, Wang Y, Ma R, et al. Tumor lysis syndrome associated with monoclonal antibodies in patients with multiple myeloma: a pharmacovigilance study based on the FAERS database. Clin Pharmacol Ther. 2023;114:211\u20139.","journal-title":"Clin Pharmacol Ther"},{"key":"3274_CR22","doi-asserted-by":"publisher","first-page":"1039867","DOI":"10.3389\/fphar.2022.1039867","volume":"13","author":"J Zhou","year":"2022","unstructured":"Zhou J, Wei Z, Xu B, Liu M, Xu R, Wu X. Pharmacovigilance of triazole antifungal agents: analysis of the FDA adverse event reporting system (FAERS) database. Front Pharmacol. 2022;13:1039867.","journal-title":"Front Pharmacol"},{"key":"3274_CR23","doi-asserted-by":"publisher","first-page":"7882277","DOI":"10.1155\/2022\/7882277","volume":"2022","author":"W Ren","year":"2022","unstructured":"Ren W, Wang W, Guo Y. Analysis of adverse reactions of aspirin in prophylaxis medication Based on FAERS database. Comput Math Methods Med. 2022;2022:7882277.","journal-title":"Comput Math Methods Med"},{"key":"3274_CR24","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1016\/j.jaip.2020.09.021","volume":"9","author":"RJ Yu","year":"2021","unstructured":"Yu RJ, Krantz MS, Phillips EJ, Stone CA. Emerging causes of drug-induced anaphylaxis: a review of anaphylaxis-associated reports in the fda adverse event reporting system (FAERS). J Allergy Clin Immunol Pract. 2021;9:819\u2013829.e2.","journal-title":"J Allergy Clin Immunol Pract"},{"key":"3274_CR25","doi-asserted-by":"publisher","first-page":"3695101","DOI":"10.1155\/2020\/3695101","volume":"2020","author":"Y Hu","year":"2020","unstructured":"Hu Y, Bai Z, Tang Y, Liu R, Zhao B, Gong J, et al. Fournier gangrene associated with sodium-glucose cotransporter-2 inhibitors: a pharmacovigilance study with data from the U.S. FDA Adverse event reporting system. J Diabetes Res. 2020;2020:3695101.","journal-title":"J Diabetes Res"},{"key":"3274_CR26","doi-asserted-by":"publisher","first-page":"1043789","DOI":"10.3389\/fendo.2022.1043789","volume":"13","author":"L Liu","year":"2022","unstructured":"Liu L, Chen J, Wang L, Chen C, Chen L. Association between different GLP-1 receptor agonists and gastrointestinal adverse reactions: a real-world disproportionality study based on FDA adverse event reporting system database. Front Endocrinol (Lausanne). 2022;13:1043789.","journal-title":"Front Endocrinol (Lausanne)"},{"key":"3274_CR27","first-page":"CD013674","volume":"5","author":"SE Hetrick","year":"2021","unstructured":"Hetrick SE, McKenzie JE, Bailey AP, Sharma V, Moller CI, Badcock PB, et al. New generation antidepressants for depression in children and adolescents: a network meta-analysis. Cochrane Database Syst Rev. 2021;5:CD013674.","journal-title":"Cochrane Database Syst Rev"},{"key":"3274_CR28","doi-asserted-by":"publisher","first-page":"995","DOI":"10.1007\/s40264-013-0061-7","volume":"36","author":"O Sauzet","year":"2013","unstructured":"Sauzet O, Carvajal A, Escudero A, Molokhia M, Cornelius VR. Illustration of the weibull shape parameter signal detection tool using electronic healthcare record data. Drug Saf. 2013;36:995\u20131006.","journal-title":"Drug Saf"},{"key":"3274_CR29","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1002\/pds.668","volume":"11","author":"EP van Puijenbroek","year":"2002","unstructured":"van Puijenbroek EP, Bate A, Leufkens HGM, Lindquist M, Orre R, Egberts ACG. A comparison of measures of disproportionality for signal detection in spontaneous reporting systems for adverse drug reactions. Pharmacoepidemiol Drug Saf. 2002;11:3\u201310.","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"3274_CR30","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1177\/0962280211403604","volume":"22","author":"GN Nor\u00e9n","year":"2013","unstructured":"Nor\u00e9n GN, Hopstadius J, Bate A. Shrinkage observed-to-expected ratios for robust and transparent large-scale pattern discovery. Stat Methods Med Res. 2013;22:57\u201369.","journal-title":"Stat Methods Med Res"},{"key":"3274_CR31","doi-asserted-by":"publisher","first-page":"910","DOI":"10.1002\/pds.5624","volume":"32","author":"P Trillenberg","year":"2023","unstructured":"Trillenberg P, Sprenger A, Machner B. Sensitivity and specificity in signal detection with the reporting odds ratio and the information component. Pharmacoepidemiol Drug Saf. 2023;32:910\u20137.","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"3274_CR32","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1007\/s11095-020-02801-3","volume":"37","author":"Y Noguchi","year":"2020","unstructured":"Noguchi Y, Tachi T, Teramachi H. Comparison of signal detection algorithms based on frequency statistical model for drug-drug interaction using spontaneous reporting systems. Pharm Res. 2020;37:86.","journal-title":"Pharm Res"},{"key":"3274_CR33","doi-asserted-by":"publisher","first-page":"e25221","DOI":"10.1371\/journal.pone.0025221","volume":"6","author":"N Anderson","year":"2011","unstructured":"Anderson N, Borlak J. Correlation versus causation? Pharmacovigilance of the analgesic flupirtine exemplifies the need for refined spontaneous ADR reporting. PLoS One. 2011;6:e25221.","journal-title":"PLoS One"},{"key":"3274_CR34","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1093\/ijnp\/pyac031","volume":"25","author":"M Fusaroli","year":"2022","unstructured":"Fusaroli M, Raschi E, Giunchi V, Menchetti M, Rimondini Giorgini R, De Ponti F, et al. Impulse control disorders by dopamine partial agonists: a pharmacovigilance-pharmacodynamic assessment through the FDA adverse event reporting system. Int J Neuropsychopharmacol. 2022;25:727\u201336.","journal-title":"Int J Neuropsychopharmacol"},{"key":"3274_CR35","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1007\/s10549-020-06001-w","volume":"186","author":"E Raschi","year":"2021","unstructured":"Raschi E, Fusaroli M, Ardizzoni A, Poluzzi E, De Ponti F. Cyclin-dependent kinase 4\/6 inhibitors and interstitial lung disease in the FDA adverse event reporting system: a pharmacovigilance assessment. Breast Cancer Res Treat. 2021;186:219\u201327.","journal-title":"Breast Cancer Res Treat"},{"key":"3274_CR36","doi-asserted-by":"publisher","first-page":"628","DOI":"10.1016\/j.tem.2022.06.005","volume":"33","author":"K Horska","year":"2022","unstructured":"Horska K, Ruda-Kucerova J, Skrede S. GLP-1 agonists: superior for mind and body in antipsychotic-treated patients? Trends Endocrinol Metab. 2022;33:628\u201338.","journal-title":"Trends Endocrinol Metab"},{"key":"3274_CR37","doi-asserted-by":"publisher","first-page":"2117","DOI":"10.1056\/NEJMoa1916038","volume":"382","author":"AS Kelly","year":"2020","unstructured":"Kelly AS, Auerbach P, Barrientos-Perez M, Gies I, Hale PM, Marcus C, et al. A randomized, controlled trial of liraglutide for adolescents with obesity. N Engl J Med. 2020;382:2117\u201328.","journal-title":"N Engl J Med"},{"key":"3274_CR38","doi-asserted-by":"publisher","first-page":"1529","DOI":"10.1111\/dom.12963","volume":"19","author":"PM O\u2019Neil","year":"2017","unstructured":"O\u2019Neil PM, Aroda VR, Astrup A, Kushner R, Lau DCW, Wadden TA, et al. Neuropsychiatric safety with liraglutide 3.0 mg for weight management: Results from randomized controlled phase 2 and 3a trials. Diabetes Obes Metab. 2017;19:1529\u201336.","journal-title":"Diabetes Obes Metab"},{"key":"3274_CR39","doi-asserted-by":"publisher","first-page":"1238353","DOI":"10.3389\/fpsyt.2023.1238353","volume":"14","author":"J-R Li","year":"2023","unstructured":"Li J-R, Cao J, Wei J, Geng W. Case report: Semaglutide-associated depression: a report of two cases. Front Psychiatry. 2023;14:1238353.","journal-title":"Front Psychiatry"},{"key":"3274_CR40","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1016\/j.jad.2012.07.010","volume":"145","author":"G Klinitzke","year":"2013","unstructured":"Klinitzke G, Steinig J, Bl\u00fcher M, Kersting A, Wagner B. Obesity and suicide risk in adults\u2013a systematic review. J Affect Disord. 2013;145:277\u201384.","journal-title":"J Affect Disord"},{"key":"3274_CR41","doi-asserted-by":"publisher","first-page":"114917","DOI":"10.1016\/j.psychres.2022.114917","volume":"318","author":"BE da Silva Bandeira","year":"2022","unstructured":"da Silva Bandeira BE, Dos Santos J\u00fanior A, Dalgalarrondo P, de Azevedo RCS, Celeri EHVR. Nonsuicidal self-injury in undergraduate students: a cross-sectional study and association with suicidal behavior. Psychiatry Res. 2022;318:114917.","journal-title":"Psychiatry Res"},{"key":"3274_CR42","doi-asserted-by":"publisher","first-page":"1170127","DOI":"10.3389\/fendo.2023.1170127","volume":"14","author":"Y Yan","year":"2023","unstructured":"Yan Y, Gong Y, Jiang M, Gao Y, Guo S, Huo J, et al. Utilization of glucagon-like peptide-1 receptor agonists in children and adolescents in China: a real-world study. Front Endocrinol (Lausanne). 2023;14:1170127.","journal-title":"Front Endocrinol (Lausanne)"},{"key":"3274_CR43","doi-asserted-by":"publisher","first-page":"113998","DOI":"10.1016\/j.psychres.2021.113998","volume":"301","author":"JP Dub\u00e9","year":"2021","unstructured":"Dub\u00e9 JP, Smith MM, Sherry SB, Hewitt PL, Stewart SH. Suicide behaviors during the COVID-19 pandemic: a meta-analysis of 54 studies. Psychiatry Res. 2021;301:113998.","journal-title":"Psychiatry Res"},{"key":"3274_CR44","doi-asserted-by":"publisher","first-page":"116776","DOI":"10.1016\/j.lfs.2019.116776","volume":"234","author":"H Yaribeygi","year":"2019","unstructured":"Yaribeygi H, Sathyapalan T, Sahebkar A. Molecular mechanisms by which GLP-1 RA and DPP-4i induce insulin sensitivity. Life Sci. 2019;234:116776.","journal-title":"Life Sci"},{"key":"3274_CR45","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1517\/17425255.2013.731394","volume":"9","author":"MJ Jespersen","year":"2013","unstructured":"Jespersen MJ, Knop FK, Christensen M. GLP-1 agonists for type 2 diabetes: pharmacokinetic and toxicological considerations. Expert Opin Drug Metab Toxicol. 2013;9:17\u201329.","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"3274_CR46","first-page":"1500","volume":"59","author":"MF Gliatto","year":"1999","unstructured":"Gliatto MF, Rai AK. Evaluation and treatment of patients with suicidal ideation. Am Fam Physician. 1999;59:1500\u20136.","journal-title":"Am Fam Physician"},{"key":"3274_CR47","doi-asserted-by":"publisher","first-page":"1128387","DOI":"10.3389\/fphar.2023.1128387","volume":"14","author":"V Battini","year":"2023","unstructured":"Battini V, Van Manen RP, Gringeri M, Mosini G, Guarnieri G, Bombelli A, et al. The potential antidepressant effect of antidiabetic agents: New insights from a pharmacovigilance study based on data from the reporting system databases FAERS and VigiBase. Front Pharmacol. 2023;14:1128387.","journal-title":"Front Pharmacol"},{"key":"3274_CR48","doi-asserted-by":"publisher","first-page":"121546","DOI":"10.1016\/j.lfs.2023.121546","volume":"320","author":"AB Darwish","year":"2023","unstructured":"Darwish AB, El Sayed NS, Salama AAA, Saad MA. Dulaglutide impedes depressive-like behavior persuaded by chronic social defeat stress model in male C57BL\/6 mice: Implications on GLP-1R and cAMP\/PKA signaling pathway in the hippocampus. Life Sci. 2023;320:121546.","journal-title":"Life Sci"},{"key":"3274_CR49","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1001\/jama.2021.23619","volume":"327","author":"DM Rubino","year":"2022","unstructured":"Rubino DM, Greenway FL, Khalid U, O\u2019Neil PM, Rosenstock J, S\u00f8rrig R, et al. Effect of weekly subcutaneous semaglutide vs daily liraglutide on body weight in adults with overweight or obesity without diabetes: the STEP 8 randomized clinical trial. JAMA. 2022;327:138\u201350.","journal-title":"JAMA"},{"key":"3274_CR50","doi-asserted-by":"publisher","first-page":"1414","DOI":"10.1001\/jama.2021.3224","volume":"325","author":"D Rubino","year":"2021","unstructured":"Rubino D, Abrahamsson N, Davies M, Hesse D, Greenway FL, Jensen C, et al. Effect of continued weekly subcutaneous semaglutide vs placebo on weight loss maintenance in adults with overweight or obesity: the STEP 4 randomized clinical trial. JAMA. 2021;325:1414\u201325.","journal-title":"JAMA"},{"key":"3274_CR51","doi-asserted-by":"publisher","first-page":"1403","DOI":"10.1001\/jama.2021.1831","volume":"325","author":"TA Wadden","year":"2021","unstructured":"Wadden TA, Bailey TS, Billings LK, Davies M, Frias JP, Koroleva A, et al. Effect of subcutaneous semaglutide vs placebo as an adjunct to intensive behavioral therapy on body weight in adults with overweight or obesity: the STEP 3 randomized clinical trial. JAMA. 2021;325:1403\u201313.","journal-title":"JAMA"},{"key":"3274_CR52","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1016\/S0140-6736(21)00213-0","volume":"397","author":"M Davies","year":"2021","unstructured":"Davies M, F\u00e6rch L, Jeppesen OK, Pakseresht A, Pedersen SD, Perreault L, et al. Semaglutide 2\u00b74 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial. Lancet. 2021;397:971\u201384.","journal-title":"Lancet"},{"key":"3274_CR53","doi-asserted-by":"publisher","first-page":"796","DOI":"10.7150\/ijms.6048","volume":"10","author":"T Sakaeda","year":"2013","unstructured":"Sakaeda T, Tamon A, Kadoyama K, Okuno Y. Data mining of the public version of the FDA adverse event reporting system. Int J Med Sci. 2013;10:796\u2013803.","journal-title":"Int J Med Sci"},{"key":"3274_CR54","doi-asserted-by":"publisher","first-page":"420","DOI":"10.3390\/healthcare10030420","volume":"10","author":"MA Khaleel","year":"2022","unstructured":"Khaleel MA, Khan AH, Ghadzi SMS, Adnan AS, Abdallah QM. A Standardized dataset of a spontaneous adverse event reporting system. Healthcare (Basel). 2022;10:420.","journal-title":"Healthcare (Basel)"},{"key":"3274_CR55","doi-asserted-by":"crossref","unstructured":"McIntyre RS, Mansur RB, Rosenblat JD, Kwan ATH. The association between glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and suicidality: reports to the Food and Drug Administration Adverse Event Reporting System (FAERS). Expert Opin Drug Saf. 2023;1\u20139.\u00a0Online ahead of print.","DOI":"10.1080\/14740338.2023.2295397"},{"key":"3274_CR56","doi-asserted-by":"publisher","first-page":"e99","DOI":"10.1192\/j.eurpsy.2023.2474","volume":"66","author":"C Chen","year":"2023","unstructured":"Chen C, Zhou R, Fu F, Xiao J. Postmarket safety profile of suicide\/self-injury for GLP-1 receptor agonist: a real-world pharmacovigilance analysis. Eur Psychiatry. 2023;66:e99.","journal-title":"Eur Psychiatry"},{"key":"3274_CR57","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-023-02672-2","author":"W Wang","year":"2024","unstructured":"Wang W, Volkow ND, Berger NA, Davis PB, Kaelber DC, Xu R. Association of semaglutide with risk of suicidal ideation in a real-world cohort. Nat Med. 2024. https:\/\/doi.org\/10.1038\/s41591-023-02672-2.","journal-title":"Nat Med"}],"container-title":["BMC Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12916-024-03274-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12916-024-03274-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12916-024-03274-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,17]],"date-time":"2024-02-17T11:06:52Z","timestamp":1708168012000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcmedicine.biomedcentral.com\/articles\/10.1186\/s12916-024-03274-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,14]]},"references-count":57,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["3274"],"URL":"https:\/\/doi.org\/10.1186\/s12916-024-03274-6","relation":{},"ISSN":["1741-7015"],"issn-type":[{"value":"1741-7015","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,2,14]]},"assertion":[{"value":"18 August 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 January 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 February 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Ethical approval was not required as the study was conducted using de-identified publicly available data.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"65"}}